Hierowski M T, Wettler O, Schally A V
Biomed Pharmacother. 1984;38(6):297-303.
Plasminogen activator and nonspecific proteolytic activity in transplantable squamous cell rat prostate tumor 11095 were measured by a fluorometric method. Prostate tumors which regressed after treatment with D-Trp-6-LH-RH had 10-fold lower concentrations of plasminogen activator(s) per mg of protein, and considerably higher levels of nuclear androgen receptor. On the other hand, there were no significant changes in nonspecific proteolytic activity in tumor tissue between untreated and D-Trp-6-LH-RH treated rats. The prostate tumor had at least three different plasminogen activator-like bands, as determined by polyacrylamide gel electrophoresis with plasminogen as substrate. The decreased activity of plasminogen activator(s) and considerably higher levels of nuclear androgen receptors correlate with the regression of prostate tumors induced by the treatment of rats with D-Trp-6-LH-RH.
采用荧光法测定了可移植性大鼠前列腺肿瘤11095中的纤溶酶原激活物和非特异性蛋白水解活性。经D-Trp-6-LH-RH治疗后消退的前列腺肿瘤,每毫克蛋白质中纤溶酶原激活物的浓度低10倍,且核雄激素受体水平显著更高。另一方面,未治疗和经D-Trp-6-LH-RH治疗的大鼠肿瘤组织中的非特异性蛋白水解活性没有显著变化。以纤溶酶原为底物进行聚丙烯酰胺凝胶电泳测定,前列腺肿瘤至少有三条不同的纤溶酶原激活物样条带。纤溶酶原激活物活性降低和核雄激素受体水平显著升高与用D-Trp-6-LH-RH治疗大鼠诱导的前列腺肿瘤消退相关。